News and information relevant to AlfaGene's endeavors is listed below.



Top Stories

July 20, 2009

Newspaper article in The Hindu concerning the signing of the MOU Agreement

Between AlfaGene Bioscience, Inc. and JSS University


July 16, 2009

Signing of "Memorandum of Understanding" (MOU) Agreement

Between AlfaGene Bioscience, Inc. and JSS University

AlfaGene Biosciences (AGB) and Jagadguru Sri Shivarathreeshwara University (JSSU), two biomedical and biotechnology focused organizations signed a memorandum of understanding (MOU) agreement, agreeing to “explore opportunities for cooperation and collaboration with each other in the field of biotechnology and research related work.”  The memorandum’s purpose is to create a shared program for human adult stem cell treatment research and applications, initially focusing on inflammatory diseases and cancers of the gastrointestinal tract such as Crohn’s Disease, Ulcerative Colitis, and colon cancer.

     AlfaGene, a USA corporation focusing on human adult stem cells of the gastrointestinal tract (GI), is a rising resource for GI clinical research and biopharmaceutical production.  The company was founded in 2007 by Mayur Doshi and Dr. Asit Panja to take advantage of its own proprietary technology for the isolation and establishment of adult stem cell lines from human patients for biomarker discovery and stem cell therapy for the treatment of GI disorders.  AlfaGene is the only entity to posses viable human adult stem cells from every region/tissue of the human GI tract.  Mr Doshi, CEO of AlfaGene, is also CEO of Apogee Pharma, has more than 20 years of experience in the global generic pharmaceutical market, and has several philanthropic endeavors.  Dr. Panja, MD, CSO of AlfaGene, has over 20 years of academic experience and is the individual who originally invented the procedure for isolation, long term culturing, and establishment of adult stem cell lines from human GI tissues, as well as, the processes for deriving primary non-transformed epithelial cell lines from these established adult stem cell lines.  JSSU was founded in1956 and presently has over 350 affiliated schools in India, offering education for a broad spectrum of healthcare and science careers.  JSSU’s vice chancellor, Dr. Bhojraj Suresh, MPharm PhD DSc, who is also President of both the Pharmacy Council of India and the Indian Pharmaceutical Association, signed this “Memorandum of Understanding” along with AlfaGene’s CSO Dr. Asit Panja, while visiting AlfaGene’s stem cell research facility in Somerset, New Jersey (US).

     For AlfaGene, JSSU provides access to patients, biological samples, clinical study collaborations, and the extensive clinical expertise of JSSU.  In return, JSSU will gain access to the human adult stem cell research related expertise and scientific staff of AlfaGene.  JSSU and AlfaGene will share in collaborative research efforts and AlfaGene will also provide an additional academic resource to JSSU by way of the scientists and facilities of AlfaGene Bioscience.  Dr. David Harrison, AlfaGene’s Director of Biomarker Discovery and Development, was excited over the prospect of future joint ventures between the two entities, as well as, the sharing of resources and ideas.  He further expressed that the benefits and potential opportunities such a collaboration will provide to both entities was a win-win solution for all involved and a prime example of the progress that can be accomplished and good will developed when entities from different countries come together to share resources. Also in attendence for the signing were Sreedhar Venkatraman, Controller of AlphaGene, Ashish Mahajan, Director of Business Development of AlfaGene, Dr. Muthusamy Shanmugam, PhD JSS Alumni, and Dr. Satish Palaniappan, PhD also a JSS Alumni.

    Dr. Asit Panja stated that “this collaboration between JSSU and AlfaGene Bioscience is truly an excellent representative example of the ever growing trend of Indian and American organizations joining forces in the name of progress for the benefit and betterment of mankind.”


May 30-June 4, 2009

AlfaGene gives two poster presentations at Digestive Disease Week 2009 in Chicago, IL

Both Dr. Panja and Dr. Harrison, members of AlfaGene's Research Team, attended and presented posters at Digestive Disease Week (DDW) 2009 in Chicago, IL.  This was the 40th anniversary of DDW which has grown into the world's largest educational forum for digestive disease academicians, clinicians, researchers and trainees, as well as, practice managers and other GI health professionals.  The meeting had more than 16,000 attendees and over 2,000 sessions and posters.  Sponsoring societies included: American Association for the Study of Liver Diseases (AASLD), American Gastro   (AGA Institute), American Society for Gastrointestinal Endoscopy (ASGE), and Society for Surgery of the Alimentary Tract (SSAT). 

PDF files of the two posters presented by AlfaGene's Research Team members can be downloaded

by clicking on the links (picture of poster) provided below. 

Mechanism of Anti-Inflammatory Action of 5-ASA on Intestinal Epithelium

Asit Panja 




Differential TLR Expression Profile in Both Epithelial Stem Cells (Epi-SC) Isolated From Each Segment of the Human Intestinal Tract and Primary Non-Transformed Epithelial Cell Lineages Derived From the Cultured Epi-SCs.

David A. Harrison, Shazia Ahmedi, and Asit Panja





March 5, 2009

AlfaGene releases 2nd brochure and launches first product line.

AlfaGene released its 2nd brochure today and launched it's first commercial product line: human adult stem cell lines derived from 10 GI tissues/regions and assorted primary epithelial cell lines derived from the adult stem cell lines.  A PDF of the

A PDF file of the brochure (altered for easy printing) can be downloaded

by clicking on the link (picture of the brochure) provided below. 

AlfaGene brochure.







Feb 2, 2009

AlfaGene awarded provisional patent 61/04726

AlfaGene was awarded a provisional patent for "Drug Discovery Methods involving a Preclinical in vitro isolated Gastrointestinal Epithelial Stem Cell–like Progenitor Cell System (US provisional patent application 61/047296).